glutathione transferase in lung cancer Anti-human activities and survey of reductase and glutathione S inhibition properties with molecular modeling studies of 2′-hydroxy-5′-methyl-3′-nitroacetophenone: a pre-clinical trial study Glutathione S-transferases and their implications

Gutierrez 1 , Zheng Kang 1 , Zoe Boyer-Diaz 2 , Arantza Lamas Paz 1 , Javier Vaquero 3,4 , Rafael Baares 3,4 , Jaime Bosch 2,4,5 , Jordi Gracia-Sancho 2,4,5 , Jonel Trebicka 6,7 , Yulia Nevzorova 1,3,4 , Carlos Sanz-Garca 1 and Francisco Javier Cubero 1,3,4 , (1)Complutense University School of Medicine, (2)Idibaps, (3)Instituto De Investigacin Sanitaria Gregorio Maran (IiSGM), (4)Centro De Investigacin Biomdica En Red De Enfermedades Hepticas y Digestivas (CIBEREHD), (5)University of Bern, (6)University Clinic Frankfurt, (7)European Foundation for the Study of Chronic Liver Failure and Grifols Chair, Barcelona, Spain Background: Patients with advanced liver fibrosis are frequently treated with statins

trial protocol (500 mg/day is between the 250 mg and 1,000 mg doses studied)

One study of NAD-deficient patients found that administering high-dose niacin (B3) an NAD precursor increased blood NAD+ and enhanced muscle strength in all subjects treated

Chronic hepatosplenomegaly in African school children: a common but neglected morbidity associated with schistosomiasis and malaria